These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 30648519)

  • 41. Interventions for treating lymphocytic colitis.
    Chande N; Al Yatama N; Bhanji T; Nguyen TM; McDonald JW; MacDonald JK
    Cochrane Database Syst Rev; 2017 Jul; 7(7):CD006096. PubMed ID: 28702956
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Olanzapine for the prevention and treatment of cancer-related nausea and vomiting in adults.
    Sutherland A; Naessens K; Plugge E; Ware L; Head K; Burton MJ; Wee B
    Cochrane Database Syst Rev; 2018 Sep; 9(9):CD012555. PubMed ID: 30246876
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Combined androgen blockade with nonsteroidal antiandrogens for advanced prostate cancer: a systematic review.
    Schmitt B; Wilt TJ; Schellhammer PF; DeMasi V; Sartor O; Crawford ED; Bennett CL
    Urology; 2001 Apr; 57(4):727-32. PubMed ID: 11306391
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.
    Sbidian E; Chaimani A; Afach S; Doney L; Dressler C; Hua C; Mazaud C; Phan C; Hughes C; Riddle D; Naldi L; Garcia-Doval I; Le Cleach L
    Cochrane Database Syst Rev; 2020 Jan; 1(1):CD011535. PubMed ID: 31917873
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Cannabinoids for nausea and vomiting in adults with cancer receiving chemotherapy.
    Smith LA; Azariah F; Lavender VT; Stoner NS; Bettiol S
    Cochrane Database Syst Rev; 2015 Nov; 2015(11):CD009464. PubMed ID: 26561338
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Early versus deferred standard androgen suppression therapy for advanced hormone-sensitive prostate cancer.
    Kunath F; Jensen K; Pinart M; Kahlmeyer A; Schmidt S; Price CL; Lieb V; Dahm P
    Cochrane Database Syst Rev; 2019 Jun; 6(6):CD003506. PubMed ID: 31194882
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Which patients with metastatic hormone-sensitive prostate cancer benefit from docetaxel: a systematic review and meta-analysis of individual participant data from randomised trials.
    Vale CL; Fisher DJ; Godolphin PJ; Rydzewska LH; Boher JM; Burdett S; Chen YH; Clarke NW; Fizazi K; Gravis G; James ND; Liu G; Matheson D; Murphy L; Oldroyd RE; Parmar MKB; Rogozinska E; Sfumato P; Sweeney CJ; Sydes MR; Tombal B; White IR; Tierney JF;
    Lancet Oncol; 2023 Jul; 24(7):783-797. PubMed ID: 37414011
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials. Prostate Cancer Trialists' Collaborative Group.
    Lancet; 2000 Apr; 355(9214):1491-8. PubMed ID: 10801170
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Bisphosphonates for advanced prostate cancer.
    Macherey S; Monsef I; Jahn F; Jordan K; Yuen KK; Heidenreich A; Skoetz N
    Cochrane Database Syst Rev; 2017 Dec; 12(12):CD006250. PubMed ID: 29278410
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Teriflunomide for multiple sclerosis.
    He D; Zhang C; Zhao X; Zhang Y; Dai Q; Li Y; Chu L
    Cochrane Database Syst Rev; 2016 Mar; 3(3):CD009882. PubMed ID: 27003123
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial.
    Fizazi K; Tran N; Fein L; Matsubara N; Rodriguez-Antolin A; Alekseev BY; Özgüroğlu M; Ye D; Feyerabend S; Protheroe A; Sulur G; Luna Y; Li S; Mundle S; Chi KN
    Lancet Oncol; 2019 May; 20(5):686-700. PubMed ID: 30987939
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Interventions for the treatment of oral and oropharyngeal cancers: targeted therapy and immunotherapy.
    Chan KK; Glenny AM; Weldon JC; Furness S; Worthington HV; Wakeford H
    Cochrane Database Syst Rev; 2015 Dec; 2015(12):CD010341. PubMed ID: 26625332
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Trastuzumab-containing regimens for metastatic breast cancer.
    Balduzzi S; Mantarro S; Guarneri V; Tagliabue L; Pistotti V; Moja L; D'Amico R
    Cochrane Database Syst Rev; 2014 Jun; 2014(6):CD006242. PubMed ID: 24919460
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Intravesical Bacillus Calmette-Guérin with interferon-alpha versus intravesical Bacillus Calmette-Guérin for treating non-muscle-invasive bladder cancer.
    Shepherd AR; Shepherd E; Brook NR
    Cochrane Database Syst Rev; 2017 Mar; 3(3):CD012112. PubMed ID: 28268259
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Non-steroidal antiandrogen monotherapy compared with luteinizing hormone-releasing hormone agonists or surgical castration monotherapy for advanced prostate cancer: a Cochrane systematic review.
    Kunath F; Grobe HR; Rücker G; Motschall E; Antes G; Dahm P; Wullich B; Meerpohl JJ
    BJU Int; 2015 Jul; 116(1):30-6. PubMed ID: 25523493
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Maximal androgen blockade for advanced prostate cancer.
    Schmitt B; Bennett C; Seidenfeld J; Samson D; Wilt T
    Cochrane Database Syst Rev; 2000; 1999(2):CD001526. PubMed ID: 10796804
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Nilutamide approved for metastatic prostate cancer.
    Am J Health Syst Pharm; 1996 Dec; 53(23):2784. PubMed ID: 8957341
    [No Abstract]   [Full Text] [Related]  

  • 58. Nilutamide response after flutamide failure in post-orchiectomy progressive prostate cancer.
    Eastham JA; Sartor O
    J Urol; 1998 Mar; 159(3):990. PubMed ID: 9474206
    [No Abstract]   [Full Text] [Related]  

  • 59. Burden of Metastatic Castrate Naive Prostate Cancer Patients, to Identify Men More Likely to Benefit from Early Docetaxel: Further Analyses of CHAARTED and GETUG-AFU15 Studies.
    Gravis G; Boher JM; Chen YH; Liu G; Fizazi K; Carducci MA; Oudard S; Joly F; Jarrard DM; Soulie M; Eisenberger MJ; Habibian M; Dreicer R; Garcia JA; Hussain MHM; Kohli M; Vogelzang NJ; Picus J; DiPaola R; Sweeney C
    Eur Urol; 2018 Jun; 73(6):847-855. PubMed ID: 29475737
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Efficacy and safety of sugammadex versus neostigmine in reversing neuromuscular blockade in adults.
    Hristovska AM; Duch P; Allingstrup M; Afshari A
    Cochrane Database Syst Rev; 2017 Aug; 8(8):CD012763. PubMed ID: 28806470
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.